To be more precise "melkein maalissa" would more closely translate to "almost at the goal" rather than "almost finished". "Melkein maalissa" carries a strong positive connotation (in a future sense); a sign of relief to come. Still, sometimes, if "melkein maalissa" is used in a past sense it carries a negative aspect; "he was almost at the goal but then X happened". Good thing the article is looking forward, and we are too! ;)
My two quick cents. On the financial side not much will happen until (again) the Nasdaq and AIM prices meet, and Lago & co. are at work. This seems to be futile, though, as AIM does not want to rise and Nasdaq has plenty of buying pressure, so the price always goes back up from the small dips. On the other side.. it's just a waiting game. Investors want results from the trials, patients want results from the trials etc.; the whole market is anxiously waiting for results from all of these trials as we can see from yesterday's situation in the Western marketplaces, especially Europe.
Faron again represented on one of the Finnish financial news site (one which I value, too). It is one of the first ones in Finnish (that I've seen) where Faron has been treated as a company, and not just a topic of superlative journalism. Inderes, one of the more known Finnish entities giving market analyses (on a very broad axis) has apparently given Faron a target price of 5,56 euros (I did not know Faron was under market analysis here). Article in Finnish, though. Bargain bin times might be over.
Greenman, IFN-beta 1-alpha is literally the same than IFN-beta 1-beta with a single tiny difference in the protein (/chemical) structure. When one of the cysteines (no. 17) in the amino acid sequence of the IFN-beta 1a is replaced by serine, we call that IFN-beta 1b. I'm pretty sure it has no effect on the functionality of the interferon protein. As a side note, the 1a is equivalent to the human IFN-beta.
It is very rude to shoot at the messenger. While Pots may have tendencies for the "negative press", so to speak, I've concluded that most of it is well enough informed, and thusly should be welcomed as contrast to the more commonly shared message here. Still, in a massively complicated issue such as this, care must be taken before jumping into any conclusion due to seemingly relevant new data.
"Collectively, these results demonstrate that early treatment with rIFN-ß protects the host from mortality by inhibiting virus replication and suppressing deleterious inflammatory responses to MERS-CoV infection.
Conversely, late administration of exogenous IFN-I promoted lethality via recruitment of activated IMMs and neutrophils, augmentation of the proinflammatory cytokine response, and inhibition of an optimal virus-specific T cell response."
In a mouse model, the timing of the administration of INF (beta) was crucial in tackling the MERS virus and the fatal disease. Note that this is a different Co-virus from the SARS viruses (1 & 2). MERS lethality is very high when compared to SARS viruses 1 & 2, so comparison is hard here. The article notes that the MERS data (where non-administration of INF was better than late administration) contradict with those gathered from human patients with SARS-1. Also, again, mouse models are very often quite poorly comparable to human disease models. In any case, if a conclusion would have to be made, it would be that timing might play a big role in using INF (beta) as medicinal product against respiratory viruses.
Now, we know much about Traumakine and we know it is not just IV-INF beta 1a but a monitoring system combined to individualizable treatment. Traumakine system is created to know when to treat and with how much of the substance.
I will always encourage critical thought, in both directions. The issues are more often than not quite many faceted and multidimensional, so getting closer to the true essence of things may be tough. I feel privileged that I may be of service on this regard.
These will be part of the early commercial steps of such thing called 'personalized medicine'. Been in the research rooms of universities and pitch meetings of drug company startups for merely a couple of decades max. This current decade will be the realization of this idea. Medicine will turn from random 'shock therapy' into laser sharp design therapy with fully tunable characteristics. This will become the new norm, and in the end the therapies used now will seem as archaic as prescription of garlic to battle flu season; not that you should discount those wisdoms of ye olde times, they still hold the truth in them, but are oh so incompatible with our world view of today.
Sax, that is the difference between so called 'classical' drugs and engineered drugs. These days a symptom/issue is recognized (/made up) and big data means (of molecular biotechnology) are used to recognize substances that affect it in a 'positive' way (also often made up - Can one say about many drugs that the desirable effect overcomes the side effects on average? Not really). This group is gradually reduced in size until zero or more drugs are on the shelves; rinse and repeat. The engineering aspect of the symptom/issue and then the substance allows a very deep knowledge about how the substance actually functions in a biomechanical way (around the symptom/issue, at least - again look at all the side effects). Classically some positive effect of a substance/natural product was recognized by chance and then this effect was utilized (it was obviously easier decades ago when modern medicine was making its first steps). Due to the complicated nature of the functions of many substances in our system, many are still shrouded in partial mystery, even after decades of rigorous research (look at nitroglycerin, for example). This 'mystery' aspect is why modern medical experts usually shun on natural medicinal products. It is a bit hypocritical, though, as drug companies have throughout the years patented and monetized engineered versions of these same natural extracts with gigantic profits.
Also, to not go completely off topic; IV-version of IFN-beta 1a is going to be so much more efficacious when compared to the subcutaneous version it's almost funny, if it weren't such a serious topic. Just wait for the Solidarity results.
Yes. This point was also one of my earlier productive contributions on this board; Traumakine being a kit more than just a simple drug. Add in lyophilized (freeze dried powder - easy to store and apparently dilute) form, and you get something that got FDA trial III approval (after a 'failure' and post hoc analysis - this is very rare) among other designations, and got into REMAP-CAP and Solidarity trials.
And remember that the stability of this stock is rather artificial due to the workings of Lago Kapital; for which they have been hired for. Everyone can see on daily basis how active they are. It is (rather) general knowledge that big time investors dislike volatility and for Faron this could be of above average importance due to the fact that they are currently closing in the turning point for the company (from money eating developer to money printing seller). The big boys can see the year 2018, so they still feel the (ever diminishing) after shakes. To discount this is to be delusional. It will rise when the key players holding the strings (quite in the open in Faron's case) are ready. There wont be any mistakes this time.
FOMO seems very strong in the current market. When there is a stagnated paper (stagnated in monthly sense) in one's portfolio, there seems to be an increased anxiety to rid oneself out of these, and hop on one of the 'other' gravy trains as fast as possible; because you might be missing out on those hefty rises we see almost every day. The patience of the investors was destroyed in the cataclysmic BEAR of March and rocket powered BULL of April. Now people run around like headless chickens.
And the stream of shares to Helsinki continues. To me it seems most of these stay in the hands of regular Finnish (or Finland based) investors. I'm getting the feeling that Nasdaq wants to rise but the constant stream of 'cheap' stock keeps the volatility down. Lago doing what they are paid to do, I quess.